<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2022-11-02 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers." Since 2017, FDA has received many questions concerning implementation of the regulatory requirements of the expanded access program. In addition, FDA developed recommendations for fulfilling the new requirements for expanded access submissions promulgated in the 21st Century Cures Act...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-23785</p>
    <p><strong>Publication Date:</strong> 2022-11-02</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/11/02/2022-23785/expanded-access-to-investigational-drugs-for-treatment-use-questions-and-answers-draft-guidance-for">https://www.federalregister.gov/documents/2022/11/02/2022-23785/expanded-access-to-investigational-drugs-for-treatment-use-questions-and-answers-draft-guidance-for</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-23785</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
